Study to Investigate the Pharmacokinetics, Safety, and Tolerability of BG00012 (Dimethyl Fumarate) When Delivered to Different Regions of the Gastrointestinal Tract in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2015
Price : $35 *
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Biogen Idec
- 12 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Aug 2013 New trial record
- 01 Aug 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.